Henry Ford Health System

Wayne State University

H. Lundbeck A/s

Research Corporation Technologies, Inc.

Biomagnetic Technologies, Inc.

Qurgen, Inc.

Michael Chopp

Zhenggang Zhang

Lei Wang

Benjamin A L Buller

Rui Lan Zhang

Jianjun Wang

Qianqian Li

Mark Katakowski

Feng Jiang

Guojun Wu

Xianshuang Liu

Daniel C Morris

Yi Li

Jieli Chen

John Moran

Norman Tepley

Yi Zhang

Ning Jiang

Zheng Gang Zhang

Thomas Nikolaj Sager

Ye Xiong

Benjamin AL Buller

Mark E Katakowski

Provided herein are methods for the prevention and treatment of cardiovascular diseases and disorders in a subject diagnosed as having suffered a cerebrovascular injury by administering agents that contain or induce the expression of microRNA-126.

Compositions for use in the treatment and prevention of cardiovascular disorders resulting from cerebrovascular injury

Without limitation, a method for preventing and/or treating neuropathic pain in a subject/patient comprising administering a therapeutically effective amount of exosomes derived and isolated from mammalian cells to the subject/patient and a method of treating cancer in a subject/patient in need thereof, comprises administering a combination comprising a therapeutically effective amount of exosomes derived and isolated from mammalian cells and a chemotherapeutic agent.

Compositions for the treatment of neuropathic pain and sensitization of tumors to chemotherapies

Methods for treating a subject in need thereof are provided which include administering a pharmaceutical composition comprising a protein transduction reagent-modified reprogramming protein to the subject, wherein the protein transduction reagent is non-covalently bound to the reprogramming protein and wherein the protein transduction reagent comprises a cation reagent and a lipid. According to aspects, such methods provide delivery of protein-transduction reagent-modified reprogramming proteins to cancer cells, such as tumor cells, as well as diseased cells of diseased tissues and provide in vivo conversion of diseased cells into normal cells via protein-induced in situ cell reprogramming without administration of nucleic acids to the subject.

Methods, systems and compositions relating to cell conversion via protein-induced in-vivo cell reprogramming

Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiments also comprise the administration a composition comprising a pharmaceutically effective amount of one or more of a group comprising microRNA-146a, exosomes comprising microRNA-146a, a promoter of microRNA-146a expression, a microRNA-146a thymosin beta 4, and a phosphodiesterase 5 inhibitor to treat neurological conditions, diseases, or injuries in mammals, including in human beings.

Methods, systems, and compositions relating to MiRNA-146a

Some embodiments comprise methods, systems, and compositions to produce and/or administer modified exosomes or other vesicles containing one or more selected microRNAs, including but not limited to, miR-146b. Some embodiments also comprise the therapeutic administration and use of such modified exosomes and/or producer cells to treat mammalian brain or neurologic injuries and diseases, including in human beings.

Methods, systems, and compositions for cell-derived/vesicle-based microRNA delivery

Without limitation, some embodiments comprise a method of treatment for promoting recovery of peripheral neuropathy in a subject, including administering to a subject in need of such treatment a therapeutically effective amount of a composition comprised of thymosin beta 4, amino acid sequences LKKTET or LKKTNT, and/or any conservative variants thereof, or an agent that stimulates production of any of those materials, or a conservative variant thereof.

Methods, systems, and compositions for promoting recovery of peripheral neuropathy

Some embodiments comprise methods, systems, and compositions to promote, improve and/or increase neuronal differentiation, oligodendrocyte differentiation, or neurological outcome or function in a patient in need thereof. Some embodiments also comprise the administration a composition comprising a pharmaceutically effective amount of one or more of a group comprising microRNA-146a, a promoter of microRNA-146a expression, a microRNA-146a mimic, thymosin beta 4, and a phosphodiesterase 5 inhibitor to treat neurological conditions, disease, or injury in mammals, including in human beings.

Methods, systems, and compositions relating to miRNA-146a

Some embodiments comprise methods, systems, and compositions to produce and/or administer modified exosomes or other vesicles containing one or more selected microRNAs, including but not limited to, miR-146b. Some embodiments also comprise the therapeutic administration and use of such modified exosomes and/or producer cells to treat mammalian injuries and diseases, including in human beings.

Methods, systems, and compositions for cell-derived/vesicle-based microrna delivery

Thymosin &#x3b2;4 can be used to treat neuronal and brain injuries that are accompanied by neuronal cell death or injury, including injuries caused by stroke or trauma and injuries caused by neurological and neurodegenerative disease. In particular, stroke and multiple sclerosis are examples of conditions which may be ameliorated by treatment with thymosin &#x3b2;4. Thymosin &#x3b2;4 has been found to restore neurological tissue through several effects on several neurological parameters which are improved by administration of thymosin &#x3b2;4 to a subject in need of neurological tissue restoration. For example, thymosin &#x3b2;4 improves axonal myelination, migration of neural progenitor cells, neural progenitor cell proliferation, differentiation of neural progenitor cells into mature neurons, differentiation of neural progenitor cells into mature glia, nerve regeneration, and brain remodeling at locations of brain injury.

Methods for improving neurological outcome after neural injury and neurodegenerative disease

The present invention relates a method for the treatment of intracranial bleeding comprising administration of a therapeutically effective amount of tPa and a therapeutically effective amount of carbamylated erythropoietin.

Treatment of acute ischemic stroke or intracranial bleeding with tPa and carbamylated erythropoietin

The present invention relates to a treatment of an autoimmune demyelinating disease/disorder. Also included in the present invention is the use of bone marrow stromal cells for the treatment of multiple sclerosis (MS).

Transplantation of bone marrow stromal cells for treatment of neurodegenerative diseases

There is provided a method of promoting neurogenesis by administering a therapeutic amount of a nitric oxide donor compound to a patient in need of neurogenesis promotion. Also provided is a compound for providing neurogenesis having an effective amount of a nitric oxide donor sufficient to promote neurogenesis. A nitric oxide compound for promoting neurogenesis is also provided. Further, a method of augmenting the production of brain cells and facilitating cellular structural and receptor changes by administering an effective amount of a nitric oxide donor compound to a site in need of augmentation is provided. There is provided a method of increasing both neurological and cognitive function by administering an effective amount of a nitric oxide donor compound to a patient.

Growing community of inventors

Southfield, MI, United States of America

Michael Chopp